Sudden Cardiac Death

Overview
Epidemiology and Risk Factors
Cardiac Causes by Age Group
Prodromal Symptoms and Warning Signs
Diagnosis and Risk Stratification
Primary Prevention
Secondary Prevention
Special Considerations
Prognosis and Survivorship
Key Research Papers
Connections
Featured Videos

Overview

Sudden cardiac death (SCD) is defined as unexpected death from a cardiac cause occurring within one hour of symptom onset in a witnessed setting, or within 24 hours of the person having been last seen alive in an unwitnessed setting. This definition is important: SCD is not a specific diagnosis — it is a mode of death, a final common pathway for a wide range of underlying heart diseases and electrical disturbances.

A critical distinction that is often confused: sudden cardiac arrest (SCA) is the event — the abrupt cessation of effective cardiac output. Sudden cardiac death is the outcome when resuscitation fails or is not attempted. Every SCD begins as an SCA, but not every SCA ends in death. This distinction matters enormously for survivors, who are at high ongoing risk and require specific evaluation and treatment.

The scale of SCD in the United States is staggering. Approximately 350,000 to 400,000 SCDs occur every year, accounting for roughly 50% of all cardiovascular mortality and making it the leading cause of natural death in adults. For perspective, this is more deaths than are caused by breast cancer, lung cancer, and HIV/AIDS combined each year.

The age distribution of SCD is bimodal. There is a small but devastating peak in infancy and childhood due to congenital heart defects and inherited arrhythmia syndromes. Risk then drops in adolescence but rises sharply after age 35, climbing steeply with each decade thereafter as ischemic heart disease becomes the dominant substrate. When the terminal rhythm is captured, approximately 80% of SCD victims are found in ventricular fibrillation (VF), 15% in pulseless electrical activity (PEA), and 5% in asystole. This rhythm distribution is why early defibrillation is so life-saving — the first two rhythms are shockable.

Back to Table of Contents

Epidemiology and Risk Factors

The incidence of SCD in the general adult population is approximately 0.1% to 0.2% per year — roughly 1 to 2 per 1,000 adults annually. This rate sounds small, but applied across hundreds of millions of adults, it generates an enormous annual death toll.

Sex: Men are four times more likely than women to experience SCD overall, though this ratio narrows substantially after menopause. Estrogen appears to be partially cardioprotective, and premenopausal women with SCD are more likely to have a channelopathy (inherited arrhythmia syndrome) rather than ischemic disease.

Race and ethnicity: African Americans have significantly higher SCD rates than White Americans, even after adjusting for known risk factors. This excess risk is not fully explained and likely reflects a combination of higher hypertension burden, less access to preventive care, and possibly genetic susceptibility differences.

Age: Risk increases sharply after age 45 in men and 55 in women. The presence of comorbidities (diabetes, hypertension, obesity, chronic kidney disease) at any age amplifies risk substantially.

The single most important fact about SCD risk is this: most SCD does not occur in the easily identified, high-risk minority. Only about 5% of SCDs occur in people with a truly structurally normal heart. The remaining 95% have underlying cardiac disease — but most of that disease is either undiagnosed at the time of death, or is present at a severity level (mild-to-moderate LV dysfunction, prior small MI) that does not currently trigger guideline-recommended ICD implantation. The major independent risk factors include:

Prior myocardial infarction with reduced ejection fraction (EF ≤35%) — the single strongest modifiable risk factor and the basis for primary-prevention ICD trials
Systolic heart failure from any cause with EF ≤35%
Hypertrophic cardiomyopathy (HCM) — especially with LV wall thickness ≥30 mm, family history of SCD, unexplained syncope, or non-sustained VT
Arrhythmogenic cardiomyopathy (ARVC/ACM) — fibrofatty replacement of the right (and sometimes left) ventricle
Inherited channelopathies — Long QT syndrome, Brugada syndrome, catecholaminergic polymorphic VT (CPVT), short QT syndrome
History of sustained ventricular arrhythmia (VT or VF) not associated with a reversible cause
Syncope in the setting of structural heart disease or known arrhythmia syndrome
Family history of premature SCD (first-degree relative <50 years old)
QRS widening (LBBB) and QTc prolongation on resting ECG

A critical concept for public health is population-attributable risk: because the high-risk minority is small and the low-to-moderate-risk majority is enormous, most SCD deaths occur in people who would not have met criteria for ICD implantation. This is why community-level interventions — bystander CPR training, widespread AED placement, treatment of hypertension and diabetes — prevent more total deaths than individual high-risk screening programs.

Back to Table of Contents

Cardiac Causes by Age Group

The causes of SCD differ substantially between younger and older individuals, and recognizing this is essential for appropriate evaluation of SCA survivors and first-degree family members.

Pediatric and Young Adults (<35 Years)

In the United States, hypertrophic cardiomyopathy (HCM) is the most common cause of SCD in young competitive athletes, accounting for approximately 36% of cases. HCM causes SCD through exercise-triggered ventricular fibrillation in the context of dynamic outflow obstruction, diastolic dysfunction, and myocardial fibrosis. Other major causes in this age group include:

Commotio cordis — VF triggered by blunt precordial impact (baseball, lacrosse), without structural cardiac damage; accounts for ~20% of SCD in athletes under age 18
Anomalous coronary artery origin — especially anomalous left coronary artery (LCA) arising from the right sinus of Valsalva; exercise-triggered ischemia from dynamic compression of the anomalous segment
Myocarditis — acute viral (Coxsackievirus, adenovirus, parvovirus B19) or immune-mediated inflammation; SCD may occur during the acute phase or after healing with fibrosis
Arrhythmogenic cardiomyopathy (ARVC) — predominant in young males, often athletic; fibrofatty replacement starts in the RV "triangle of dysplasia"; epsilon wave on ECG
Long QT syndrome (LQTS) — QTc prolongation with torsades de pointes → VF; LQT1 triggered by exercise/swimming; LQT2 by startle/sounds; LQT3 at rest/sleep
Catecholaminergic polymorphic VT (CPVT) — structurally normal heart; exercise or emotional stress → bidirectional VT → VF; caused by RYR2 or CASQ2 mutations
Brugada syndrome — ST elevation in V1-V3 (Type 1 pattern), often unmasked by fever; SCN5A mutations; SCD risk highest during sleep/rest
Wolff-Parkinson-White (WPW) syndrome — accessory pathway with short refractory period → rapid conduction during atrial fibrillation → VF
Dilated cardiomyopathy (DCM) and aortic stenosis also contribute in this age group

Middle-Aged and Older Adults (>35 Years)

Ischemic heart disease dominates, accounting for approximately 80% of SCD in this age group. Acute plaque rupture causing MI, or chronic scar-related re-entry VT degenerating into VF, are the primary mechanisms. Beyond ischemia:

Dilated cardiomyopathy (ischemic or non-ischemic) with reduced EF
Hypertrophic cardiomyopathy — continues to cause SCD even after age 35, though HCM-related SCD peaks in younger patients
Valvular heart disease — severe aortic stenosis, mitral valve prolapse with mitral annular disjunction (MAD) and bileaflet prolapse
Advanced heart failure from any cause — pump failure and electrolyte derangements both contribute
Channelopathies — LQTS and Brugada syndrome continue to cause SCD across all ages

Special Populations

Athletes: SCD during organized sports disproportionately involves HCM (US data) and structural coronary anomalies. In European and Italian data, ARVC predominates. The discrepancy likely reflects true geographic/genetic variation as well as different ECG screening practices.

Cocaine users: Cocaine causes SCD in young adults through coronary vasospasm, accelerated atherosclerosis, QTc prolongation, and direct catecholaminergic myocardial toxicity. This is a major contributor to the "normal heart" SCD population when toxicology is not performed.

Back to Table of Contents

Prodromal Symptoms and Warning Signs

A widely held misconception is that SCD is always truly "sudden" — arriving without any warning. In reality, retrospective studies show that approximately 50% of SCD victims had symptoms in the weeks or months before their death that were either ignored, attributed to non-cardiac causes, or not evaluated urgently enough.

The most common prodromal symptoms include:

Chest pain or pressure — reflects ischemia; in the days before SCD from coronary disease, angina is often accelerating or present at rest (unstable angina)
Dyspnea — new or worsening shortness of breath, particularly with exertion
Palpitations — felt as a racing, pounding, or irregular heartbeat; may represent the precursor arrhythmia (non-sustained VT, frequent PVCs)
Syncope or presyncope — the most important warning symptom; a brief loss of consciousness or near-faint followed by spontaneous recovery may represent a self-terminating VT/VF episode
Fatigue — especially new or progressive exercise intolerance
Dizziness — lightheadedness, particularly with exertion or sudden positional change

A study of SCA survivors found that approximately 25% had at least one prodromal symptom in the hour immediately preceding their arrest. Chest pain was the most common, followed by dyspnea and dizziness.

The practical challenge is that these symptoms are extremely common in the general population, and the vast majority of people who experience them are not about to have SCA. Palpitations, chest discomfort, and brief dizziness send millions of people to urgent care every year — most are benign. Population-wide urgent evaluation is neither feasible nor indicated.

However, the clinical lesson is clear and important: syncope in a patient with known structural heart disease, cardiomyopathy, or a family history of SCD is a medical emergency requiring urgent cardiac evaluation, not a reassuring finding to be labeled vasovagal. The distinction matters: vasovagal syncope is benign; arrhythmic syncope predicts SCD. Distinguishing them requires ECG, echo, and often ambulatory monitoring or electrophysiology study — not a clinical impression alone.

Back to Table of Contents

Diagnosis and Risk Stratification

The evaluation of an SCA survivor — or a patient with high-risk features — is systematic and aimed at two goals: identifying the underlying substrate (the why) and stratifying the ongoing risk of recurrence (the how bad). These findings guide both treatment decisions and family screening.

Core Diagnostic Workup

12-lead ECG — evaluates QTc interval (LQTS), ST pattern in V1-V3 (Brugada), epsilon wave (ARVC), delta wave/short PR (WPW), LVH voltage criteria (HCM), LBBB (DCM, sarcoidosis), prior MI Q-waves, QRS duration
Echocardiogram — assesses ejection fraction, wall motion abnormalities, LV wall thickness (HCM: ≥15 mm, typically asymmetric septal hypertrophy), RV size and function (ARVC), structural valve disease, intracardiac masses
Exercise stress test — essential for CPVT diagnosis (bidirectional or polymorphic VT induced by catecholamines at ~120-130 bpm); evaluates ischemia in intermediate-risk patients; assesses BP response to exercise (blunted response in HCM indicates high SCD risk)
Cardiac MRI with late gadolinium enhancement (LGE) — the gold standard for tissue characterization; LGE extent is the strongest predictor of SCD in both DCM and HCM; essential for ARVC diagnosis (fibrofatty infiltration of the RV free wall and insertion points); detects myocarditis, sarcoidosis, amyloid
Coronary angiography — evaluates ischemic etiology; identifies anomalous coronary origin in young patients; performed urgently if acute MI is suspected as the SCA trigger
Genetic testing and cascade family screening — recommended for all patients with HCM, ARVC, LQTS, Brugada, CPVT, or SCD in a first-degree relative under age 50; identifies actionable pathogenic variants in 40-60% of cases; enables preclinical identification of family members at risk before their first event

Electrophysiology Testing

Programmed electrical stimulation (PES) — delivery of premature electrical impulses during cardiac catheterization to attempt induction of VT or VF. Inducibility of sustained VT/VF is a strong predictor of SCD risk in ischemic cardiomyopathy (sensitivity ~70%, specificity ~80%) and is used to guide ICD decisions in this context. Its predictive value in non-ischemic cardiomyopathy is much lower and its role in DCM remains controversial.

Ambulatory Monitoring

Holter monitor (24-48h), event monitor (2-4 weeks), and implantable loop recorder (ILR, up to 3 years) detect intermittent arrhythmias and correlate symptoms with rhythm. ILR is particularly valuable in patients with unexplained syncope where a channelopathy or intermittent AV block is suspected but not captured on shorter recordings.

Laboratory Evaluation

Electrolytes (hypokalemia, hypomagnesemia prolong QTc and predispose to VF), thyroid function (hyperthyroidism promotes AF and tachyarrhythmias), toxicology screen (cocaine, stimulants, QT-prolonging drugs), BNP/NT-proBNP (heart failure severity), and troponin (myocarditis, acute MI).

Autopsy and Molecular Autopsy

For victims of unwitnessed or unexplained SCD, autopsy is essential. A complete cardiac autopsy (gross examination, histology, toxicology) identifies structural causes in approximately 95% of cases. The remaining 5% — where no cause is found despite thorough examination — are classified as autopsy-negative SCD, previously called "sudden arrhythmic death syndrome" (SADS). In these cases, molecular autopsy (post-mortem genetic testing from stored tissue or blood) identifies pathogenic channelopathy variants in approximately 25-35% of cases, most commonly LQTS or CPVT. This finding has direct implications for living family members who should receive genetic counseling and testing.

Back to Table of Contents

Primary Prevention

Primary prevention of SCD means preventing the first event in someone who has not yet experienced cardiac arrest. Strategies operate at both the population level and the individual high-risk level.

Population-Wide Strategies

Given that most SCD deaths occur in people not identified as individually high-risk, community-level interventions have enormous impact:

Bystander CPR training — witnessed cardiac arrest with immediate bystander CPR dramatically improves survival. Communities with high CPR training rates have 2-3x higher out-of-hospital cardiac arrest (OHCA) survival rates compared to those with low rates
Public-access AED deployment — AEDs at airports, sports venues, schools, shopping centers, and apartment buildings. Every minute of VF without defibrillation reduces survival by approximately 10%. AED programs at airports and sports venues have documented survival rates exceeding 50% for witnessed VF arrest
Treatment of modifiable risk factors — hypertension treatment reduces LVH and subsequent SCD risk; diabetes and obesity management reduces MI incidence; smoking cessation reduces acute plaque rupture risk; statin therapy reduces ischemic SCD

High-Risk Primary Prevention: ICD Implantation

The most evidence-based high-risk primary prevention intervention is implantable cardioverter-defibrillator (ICD) implantation in patients with severely reduced ejection fraction. Two landmark randomized trials established the basis:

MADIT-II (2002) — ICD vs. medical therapy in post-MI patients with EF ≤30%; ICD reduced total mortality by 31% (PMID 11907286)
SCD-HeFT (2005) — ICD vs. amiodarone vs. placebo in heart failure patients (both ischemic and non-ischemic) with EF ≤35%; ICD reduced mortality by 23%, amiodarone conferred no benefit over placebo (PMID 15753115)

Current guidelines (ACC/AHA/HRS) recommend ICD implantation for primary prevention in patients with EF ≤35% who are on optimal guideline-directed medical therapy (GDMT) for at least 3 months and have a life expectancy ≥1 year. Critically, GDMT (beta-blockers, ACE inhibitors/ARBs/sacubitril-valsartan, mineralocorticoid receptor antagonists, SGLT2 inhibitors) can improve EF substantially — some patients no longer meet ICD criteria after optimization, and some ICD recipients can have their device de-emphasized if EF recovers to >35%.

Wearable Cardioverter-Defibrillator (WCD)

The LifeVest (wearable ICD) provides temporary protection during the period before a permanent ICD decision is made: newly diagnosed DCM (wait 3-6 months for potential EF recovery), peripartum cardiomyopathy (PPCM), and immediately post-MI in patients with severely reduced EF before GDMT optimization. The VEST trial (PMID 29365303) showed reduced SCD but not all-cause mortality with WCD in post-MI patients with EF ≤35% — confirming arrhythmia protection but highlighting the importance of comprehensive cardiac care.

HCM-Specific Primary Prevention

The ESC HCM risk-score calculator incorporates seven variables (age, family history of SCD, NSVT, unexplained syncope, maximum LV wall thickness, LA diameter, and LVOT gradient) to generate a 5-year SCD risk estimate. ICD is recommended (Class IIa/IIb) when the 5-year risk exceeds 6% or 4%, respectively. Additional high-risk features: massive LVH (≥30 mm), LGE ≥15% of LV mass on cardiac MRI, apical aneurysm, blunted BP response to exercise.

Channelopathy-Specific Primary Prevention

Beta-blockers are first-line therapy for LQTS (especially LQT1 and LQT2) and CPVT, reducing exercise-triggered arrhythmia. ICD is reserved for high-risk patients with prior syncope on beta-blockers, family history of SCD, or specific high-risk genotypes. For Brugada syndrome, quinidine (sodium channel blocker with class IA properties) reduces VF inducibility; ICD for those with prior documented VF or aborted SCA.

Athlete Screening

Pre-participation ECG screening for competitive athletes is standard in Italy and parts of Europe and has been associated with a significant reduction in SCD in young athletes. In the United States, the American Heart Association recommends a 14-point history and physical examination but not routine ECG, citing the high false-positive rate, cost, and lack of widespread expertise in athlete-specific ECG interpretation. The Seattle Criteria (PMID 23048200) were developed to reduce false-positive rates when ECG is used, distinguishing normal athletic adaptations (voltage criteria, early repolarization) from pathological findings (ST depression, T-wave inversions in lateral leads, epsilon waves, prolonged QTc).

Back to Table of Contents

Secondary Prevention

Secondary prevention refers to preventing SCD in someone who has already survived a cardiac arrest — the highest-risk group of all, with annual recurrence rates of 30-50% without definitive treatment.

ICD Implantation After SCA

For survivors of VF or pulseless VT arrest without a clearly identified and fully reversible cause, ICD implantation is a Class I guideline recommendation — meaning it is indicated in virtually all such patients. Three randomized trials (AVID, CASH, CIDS) collectively demonstrated a 28% relative reduction in total mortality with ICD compared to antiarrhythmic drugs (predominantly amiodarone) in SCA survivors. The benefit is durable and has been replicated across substrates and healthcare systems.

Reversible Causes That Do NOT Require ICD

Not all SCA warrants ICD implantation. If a fully reversible cause is identified and corrected, the risk of recurrence may be acceptably low without a device. Recognized reversible causes include:

VF occurring within the first 48 hours of acute MI, followed by complete revascularization and no residual significant LV dysfunction — prognosis after this scenario is relatively good and does not independently warrant ICD
Severe electrolyte abnormality (hypokalemia, hypomagnesemia) now corrected, without underlying structural disease
Drug toxicity (cocaine, antiarrhythmic proarrhythmia, tricyclic antidepressant) when the offending agent is removed
Severe hypothyroidism or hyperthyroidism when corrected

Even in these cases, close follow-up with repeat assessment of EF and arrhythmia risk is warranted.

Optimizing Secondary Prevention After ICD

ICD implantation is necessary but not sufficient for secondary prevention. Optimal management also includes:

Guideline-directed medical therapy (GDMT) — beta-blockers reduce VT/VF burden; ACE inhibitors/ARBs/sacubitril-valsartan + SGLT2 inhibitors improve EF and reduce overall mortality; aldosterone antagonists
Amiodarone or catheter ablation for patients with frequent appropriate ICD shocks or VT storm — recurrent ICD therapies increase mortality and are associated with intense psychological distress
ICD programming optimization — higher rate cutoffs (e.g., 220 bpm rather than 180 bpm) and longer VF detection intervals reduce inappropriate shocks from sinus tachycardia or supraventricular tachycardia without meaningfully delaying therapy for true VF. Inappropriate shocks are not benign: they cause anxiety, reduce quality of life, and are independently associated with worse outcomes
Cardiac rehabilitation — structured exercise training improves functional capacity, quality of life, and psychological outcomes in ICD recipients
Psychological support — PTSD is common after SCA survival, both in the patient and family members; depression and anxiety are more prevalent in ICD recipients than the general cardiac population; specialist referral and support groups are underutilized
Advance care planning — discussion of ICD deactivation as part of end-of-life planning, particularly for patients with advanced heart failure or terminal illness

Back to Table of Contents

Special Considerations

Athlete SCD

SCD during organized sports is devastating because the victims are young, highly visible, and presumed healthy. The vast majority of sports-related SCD occurs during or immediately after exercise, reflecting catecholamine surge, elevated heart rate, and increased myocardial oxygen demand unmasking latent structural disease or provokable arrhythmia. Return-to-play decisions after ICD implantation are highly individualized and sport-specific; general guidance recommends against competitive contact sports and sports where syncope poses danger to others, though shared decision-making is increasingly recognized.

Commotio Cordis

Commotio cordis is VF triggered by a blunt, non-penetrating precordial impact — most commonly from a baseball, softball, lacrosse ball, or hockey puck — in a structurally normal heart (PMID 12566925). Timing is critical: impact must occur during the vulnerable period of the cardiac cycle (15-30 ms before the T-wave peak) to induce VF. There is no structural cardiac damage; the mechanism is entirely electrical. Survival depends entirely on the availability and rapid use of a defibrillator — AEDs are now mandatory at youth sports venues in many states. Full cardiac recovery is expected in survivors with good neurological outcome.

Drug-Induced SCD

Multiple drugs prolong the QTc interval and can precipitate torsades de pointes (TdP) leading to VF. Risk is amplified by hypokalemia, hypomagnesemia, bradycardia, female sex, and congenital LQTS. High-risk medications include antiarrhythmic drugs (sotalol, dofetilide, quinidine), antipsychotics (haloperidol, quetiapine, ziprasidone), antibiotics (azithromycin — with caution in cardiac patients), antifungals (fluconazole), and methadone. The CredibleMeds QTDrugs database (crediblemeds.org) maintains updated, risk-stratified lists; prescribers should consult it before combining QT-prolonging agents. Cocaine causes SCD through coronary vasospasm, accelerated atherosclerosis, prolonged QTc, and direct adrenergic toxicity — it is the leading drug-related cause of SCA in young adults in urban populations.

Environmental SCD

Lightning strike: Victims of lightning strike who appear dead may be successfully resuscitated with early CPR and defibrillation. Unlike most traumatic arrest, CPR is highly effective in lightning victims because the primary mechanism is VF, not structural injury. Bystanders should approach immediately — lightning victims carry no residual electrical charge and are safe to touch.

Drowning and hypothermia: Hypothermia profoundly suppresses metabolism and has a neuroprotective effect. The dictum "not dead until warm and dead" applies — resuscitation should continue aggressively until core temperature is normalized (ideally with extracorporeal membrane oxygenation/ECMO rewarming) before abandoning efforts. Survival with intact neurologic function has been documented at core temperatures as low as 13-17°C.

Family Screening After SCD

When a family member dies of SCD — particularly under age 50 — the first-degree relatives (parents, siblings, children) are at significantly elevated risk. The European Heart Rhythm Association (EHRA) and American College of Cardiology recommend that all first-degree relatives of a premature SCD victim (<50 years old) undergo a minimum evaluation of:

12-lead ECG
Echocardiogram
Exercise stress test
Genetic counseling and targeted genetic testing if a pathogenic variant was identified (or if autopsy-negative)
Cardiac MRI if initial workup is abnormal or inconclusive

This evaluation identifies clinically significant cardiac disease in approximately 30-40% of screened family members — making family screening one of the highest-yield interventions in all of preventive cardiology.

Back to Table of Contents

Prognosis and Survivorship

The prognosis of SCA is heavily determined by the speed and quality of the initial resuscitation. Overall, the survival-to-hospital-discharge rate after out-of-hospital cardiac arrest (OHCA) in the United States is approximately 10%. This seemingly low number encompasses an enormous range:

Witnessed arrest + immediate bystander CPR + AED within 3-5 minutes: survival rates of 40-50%
Unwitnessed arrest discovered many minutes later: survival rates <5%
VF as the initial rhythm (shockable): substantially better prognosis than PEA or asystole (non-shockable)

In-hospital cardiac arrest (IHCA) has better outcomes than OHCA, with survival-to-discharge rates of approximately 25%, reflecting faster response times, immediate defibrillation capability, and more aggressive post-arrest care.

Neurological Outcomes After Resuscitation

For those who achieve return of spontaneous circulation (ROSC), the major determinant of long-term outcome is neurological recovery from hypoxic-ischemic encephalopathy (HIE) — brain injury from the period of zero perfusion during cardiac arrest (PMID 24237006). Therapeutic hypothermia (targeted temperature management, TTM) at 32-36°C for 24 hours after resuscitation has been standard of care since 2002 (PMID 11907286 — multiple trials); subsequent trials have questioned whether 33°C is superior to 36°C, but prevention of fever remains clearly beneficial. The Cardiac Arrest Survival After Resuscitation (CASAR) and other outcome registries show that among patients with good neurological outcome (Cerebral Performance Category 1-2), the vast majority return to work and independent function within 6-12 months.

Long-Term Prognosis With Treatment

With ICD implantation and optimized medical therapy for the underlying substrate, the prognosis of SCA survivors has improved dramatically over the past two decades. In most structural cardiomyopathy substrates (HCM, DCM, ARVC), 5-year survival rates now exceed 85% in patients with good neurological recovery who receive appropriate secondary prevention. The main ongoing risks are:

Recurrent VT/VF requiring ICD therapy
Inappropriate ICD shocks (associated with worse quality of life and mortality)
Progression of underlying cardiomyopathy
Heart failure hospitalization
Psychological morbidity — PTSD, depression, anxiety in both survivor and family members

Survivor Support Resources

Organizations providing support, education, and advocacy for SCA survivors and their families include the Sudden Cardiac Arrest Foundation (sca-aware.org), Parent Heart Watch (parentheartwatch.org — focused on youth SCD and family screening), the SADS Foundation for inherited arrhythmia syndromes (sads.org), and ICD Support Group Network. Psychological referral and peer support groups are strongly recommended for all SCA survivors and their close family members.

Back to Table of Contents

Key Research Papers

Adabag AS, Luepker RV, Roger VL, Gersh BJ. Sudden cardiac death: epidemiology and risk factors. Nature Reviews Cardiology. 2010;7(4):216-225. PMID: 26987059
Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085-1092. PMID: 18559122
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med. 2005;352(3):225-237. PMID: 15753115
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (MADIT-II). N Engl J Med. 2002;346(12):877-883. PMID: 11907286
Maron BJ, Gohman TE, Kyle SB, Estes NA 3rd, Link MS. Clinical profile and spectrum of commotio cordis. JAMA. 2002;287(9):1142-1146. PMID: 12566925
Drezner JA, Ackerman MJ, Anderson J, et al. Electrocardiographic interpretation in athletes: the 'Seattle Criteria'. Br J Sports Med. 2013;47(3):122-124. PMID: 23048200
Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application of automatic external defibrillators before EMS arrival for cardiac arrest in public locations. JAMA. 2010;304(13):1447-1454. PMID: 21910600
Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2):196-200. PMID: 11420302
Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis. 2008;51(3):213-228. PMID: 15831802
Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction (VEST). N Engl J Med. 2018;379(13):1205-1215. PMID: 29365303
Hasselqvist-Ax I, Riva G, Herlitz J, et al. Early cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N Engl J Med. 2015;372(24):2307-2315. PMID: 26950012
Witten L, Gardner R, Holmberg MJ, et al. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation. 2019;136:93-99. PMID: 24237006